Biofrontera Inc
BFRI
查看详细走势图
0.766USD
+0.006+0.72%
收盘 12/19, 16:00（美东）报价延迟15分钟
8.92M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.72%
5天
-5.70%
1月
+1.65%
6月
+25.16%
今年开始到现在
-29.72%
1年
-21.72%
查看详细走势图
TradingKey Biofrontera Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Biofrontera Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名111/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biofrontera Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
6.000
目标均价
+628.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Biofrontera Inc亮点
亮点风险
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
业绩高增长
公司营业收入稳步增长，连续3年增长30.16%
业绩增长期
公司处于发展阶段，最新年度总收入37.32M美元
利润高增长
公司净利润处于行业前列，最新年度总收入37.32M美元
估值合理
公司最新PE估值-0.51，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值113.95K
Biofrontera Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biofrontera Inc简介
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
公司代码BFRI
公司Biofrontera Inc
CEOLuebbert (Hermann)
网址https://www.biofrontera-us.com/
常见问题
Biofrontera Inc(BFRI)的当前股价是多少？
Biofrontera Inc(BFRI)的当前股价是 0.766。
Biofrontera Inc的股票代码是什么？
Biofrontera Inc的股票代码是BFRI。
Biofrontera Inc股票的52周最高点是多少？
Biofrontera Inc股票的52周最高点是1.870。
Biofrontera Inc股票的52周最低点是多少？
Biofrontera Inc股票的52周最低点是0.536。
Biofrontera Inc的市值是多少？
Biofrontera Inc的市值是8.92M。
Biofrontera Inc的净利润是多少？
Biofrontera Inc的净利润为-17.76M。
现在Biofrontera Inc(BFRI)的股票是买入、持有还是卖出？
根据分析师评级，Biofrontera Inc(BFRI)的总体评级为买入，目标价格为6.000。
Biofrontera Inc(BFRI)股票的每股收益（EPS TTM）是多少
Biofrontera Inc(BFRI)股票的每股收益（EPS TTM）是-1.506。
相关品种
